ClinicalTrials.gg

Program

obrixtamig

Also written as “Obrixtamig”, “BI 764532” and “Obrixtamig - parenteral 1”.

In Boehringer Ingelheim's pipeline, DLL3/CD3 T-cell engager. Its studies are mostly in Small Cell Lung Carcinoma · Glioma, led by Boehringer Ingelheim.

Furthest: phase 3, since Apr 16, 202611 company-led studies, 11 open or runningNext primary completion: Dec 15, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim1111 open or runningphase 3since Apr 16, 2026Jun 10, 2020Dec 15, 2026phase 1 · NCT05963867
  • Named in Boehringer Ingelheim’s own pipeline as Obrixtamig (BI 764532), phase 3, as of Aug 2026 (source).

Also a collaborator on its studies: BioNTech.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 10, 2020First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT04429087 · 306 enrolled · United States, Germany, Japan and more
  2. May 22, 2023Phase 2 study in Small Cell Lung CarcinomaNCT05882058 · 204 planned · United States, Belgium, Bulgaria and more
  3. May 25, 2023Phase 1 study in Small Cell Lung CarcinomaNCT05879978 · 45 enrolled · Belgium, France, Germany and more
  4. Jun 15, 2023Phase 1 study in GliomaNCT05916313 · 20 planned · United States, Austria, Germany and more
  5. Jul 18, 2023Phase 1 study in Small Cell Lung CarcinomaNCT05963867 · 12 planned · Netherlands
  6. Aug 7, 2023Phase 1 study in Small Cell Lung CarcinomaNCT05990738 · 69 enrolled · United States, France, Germany and more
  7. Oct 5, 2023Phase 1 study in Small Cell Lung CarcinomaNCT06077500 · 46 enrolled · United States, Belgium, France and more
  8. Apr 16, 2026Phase 3 study in Extrapulmonary Neuroendocrine Cancer (epNEC)Phase 3 reachedNCT07544654 · 390 planned · United States, Argentina, Australia and more
  9. Jul 13, 2026Phase 2 study in Small Cell Lung CarcinomaNCT07707895 · 60 planned · United States, Australia, Belgium and more
  10. Sep 22, 2026Phase 2 study in Small Cell Lung CarcinomaNCT07843940 · 55 planned · United States, Australia, Belgium and more
  11. Nov 5, 2026Phase 3 study in Advanced CancerNCT07929051 · 68 planned · Belgium, France, Germany and more

Ahead

  1. Dec 15, 2026Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT05963867
  2. Mar 30, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT05990738
  3. Mar 31, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT06077500
  4. Aug 9, 2027Primary completion: phase 1 study in GliomaNCT05916313

TargetBeta

“DLL3/CD3 T-cell engager”the company's pipeline, read by Claude · source
“A bispecific T-cell engager antibody directed against both the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) and the CD3 antigen found on T-lymphocytes, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
tarlatamabruleAmgenphase 313
AlveltamigruleSuzhou Zelgen Biopharmaceuticalsphase 311
gocatamigMerckphase 34
SHR-7787Jiangsu HengRui Medicinephase 21
clesitamigHoffmann-La Rochephase 12
HLX3901Fosun Pharmaphase 11

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07929051Advanced Cancer · Belgium, France, Germany and more3Not yet recruitingJul 3, 202868
NCT07843940Small Cell Lung Carcinoma · United States, Australia, Belgium and more2RecruitingApr 17, 203055
NCT07707895Small Cell Lung Carcinoma · United States, Australia, Belgium and more2RecruitingApr 26, 203060
NCT07544654Extrapulmonary Neuroendocrine Cancer (epNEC) · United States, Argentina, Australia and more3RecruitingDec 13, 2029390
NCT06077500Small Cell Lung Carcinoma · United States, Belgium, France and more1Active, not recruitingMar 31, 202746
NCT05990738Small Cell Lung Carcinoma · United States, France, Germany and more1Active, not recruitingMar 30, 202769
NCT05963867Small Cell Lung Carcinoma · Netherlands1RecruitingDec 15, 202612
NCT05916313Glioma · United States, Austria, Germany and more1RecruitingAug 9, 202720
NCT05879978Small Cell Lung Carcinoma · Belgium, France, Germany and more1Active, not recruitingJun 11, 202545
NCT05882058Small Cell Lung Carcinoma · United States, Belgium, Bulgaria and more2RecruitingDec 17, 2027204
NCT04429087Small Cell Lung Carcinoma · United States, Germany, Japan and more1Active, not recruitingAug 31, 2026306

How it is read

Names in the registry

  • “Obrixtamig”, 5 entries
  • “BI 764532”, 4 entries
  • “Obrixtamig - parenteral 1”, 1 entry
  • “Obrixtamig - parenteral 2”, 1 entry
  • “BI 764532, dose 1”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.